OptiBiotix Health Plc Announces Final Revenue Results for the Year Ended 30 November 2019; Provides Revenue Guidance for the Fiscal 2020
The company anticipates further revenue growth in 2020 as existing deals contribute to full year revenues, partners continue to grow sales, the launch of SlimBiome® with Holland and Barrett and AlfaSigma's launch of Ezimega 3 containing LPLDL® in Italy contribute to 2020 sales and larger partners like Agropur and Akum commercialise products in home markets.